Selective serotonin re-uptake inhibitor warnings and trends in exposures reported to poison control centres in Texas

Public Health
M B Forrester

Abstract

Since January 2002, the US Food and Drug Administration (FDA) has issued a number of advisories about the use of antidepressants, including selective serotonin re-uptake inhibitors (SSRIs). These advisories may have influenced the number of SSRI exposures reported to poison control centres. The purpose of this study was to examine time trends in SSRI exposures reported to poison control centres in Texas with respect to the timing of the various advisories. Retrospective review of data from poison control centres. Cases were divided into two groups: (1) paroxetine exposures and (2) other SSRI exposures reported to poison control centres in Texas between 1998 and 2006. The month and year of the call, and patient age and gender were identified. The mean monthly number of ingestions for the two groups was calculated for six time periods related to the FDA advisories. The mean monthly number of total paroxetine ingestions between January 2002 and June 2003 was 77.6. This declined by 23.3% to 59.6 in July 2003-March 2004 after an advisory about the risk of suicidality in youths using paroxetine. Comparable mean monthly numbers for patients aged <20 years were 33.3 and 20.3, respectively (decline of 38.9%); and for patients aged >or=2...Continue Reading

References

Sep 25, 1999·The American Journal of Emergency Medicine·T L LitovitzS Lee
Sep 22, 2000·The American Journal of Emergency Medicine·T L LitovitzB E Benson
Sep 14, 2001·The American Journal of Emergency Medicine·T L LitovitzB E Benson
Feb 2, 2002·BMJ : British Medical Journal·Alison Tonks
May 1, 2002·JAMA : the Journal of the American Medical Association·Karen E LasserDavid H Bor
Jun 14, 2003·BMJ : British Medical Journal·Fabian Waechter
Oct 3, 2003·The American Journal of Emergency Medicine·William A WatsonMary E May
Nov 25, 2003·Lancet·Ivan Oransky
Oct 19, 2004·The American Journal of Emergency Medicine·William A WatsonDouglas Borys
Sep 6, 2005·The American Journal of Emergency Medicine·William A WatsonKathleen M Wruk
Dec 7, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Macey L MurrayIan C K Wong
Feb 16, 2006·Archives of Internal Medicine·Karen E LasserDavid W Bates
Oct 4, 2006·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Melisa W LaiKathleen M Wruk
Mar 3, 2007·American Journal of Public Health·Paul A KurdyakMuhammad M Mamdani
Apr 4, 2007·Archives of General Psychiatry·Charles B NemeroffAlan F Schatzberg
Apr 17, 2007·Pharmacoepidemiology and Drug Safety·Angela J DeanTreasure McGuire

❮ Previous
Next ❯

Citations

Apr 7, 2012·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sigrid PieningPeter G M Mol
Nov 7, 2017·British Journal of Clinical Pharmacology·Thomas GoedeckeXavier Kurz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.